Risk of Transmission of Creutzfeldt–Jakob Disease by Blood Transfusion

  • Alexander H. Peden
  • Mark W. Head
  • James W. Ironside
Chapter

Abstract

Early epidemiological studies on sporadic Creutzfeldt–Jakob disease did not identify blood transfusion as a risk factor for the disease. However, the emergence of variant Creutzfeldt–Jakob disease (vCJD) in 1996 and the identification of PrPSc in lymphoid tissues in this novel disorder led to concerns that transmission of infectivity by blood transfusion might be a possibility. These concerns were fully realised in 2004, when the first case of vCJD associated with transmission by blood transfusion was identified in a recipient who was a methionine homozygote at codon 129 in the prion protein gene, as in all other vCJD patients. Other similar cases have subsequently emerged, along with cases of asymptomatic vCJD infection in a blood transfusion recipient and a plasma product recipient, both of whom were heterozygous at codon 129 of the prion protein gene. This chapter reviews the experimental evidence for the transmission of prion infectivity by blood transfusion in a range of experimental models, discusses the evidence for the transmission of vCJD by blood transfusion and plasma products and considers the future possibilities for the development and potential uses of blood-based screening tests for human prion diseases.

Keywords

Blood transfusion Creutzfeldt–Jakob disease Prion disease transmission Prion protein in blood vCJD 

Notes

Acknowledgements

The work of the National CJD Research & Surveillance Unit is supported by the Department of Health, UK, and the Scottish Government. Dr. Alexander Peden has been supported by grants funding from the Scottish Government Health Directorate Chief Scientists Office. The views expressed in the publication are those of the authors and not necessarily those of the Department of Health, UK. The authors would like to thank relatives of patients for the opportunity to conduct research on tissue specimens at the National CJD Research & Surveillance Unit that contributed to the identification of blood transfusion-related transmission of variant CJD.

References

  1. Andreoletti O, Litaise C, Simmons H, Corbiere F, Lugan S, Costes P, Schelcher F, Vilette D, Grassi J, Lacroux (2012) Highly efficient prion transmission by blood transfusion. PLoS Pathog 8:e1002782PubMedCrossRefGoogle Scholar
  2. Atarashi R, Moore RA, Sim VL, Hughson AG, Dorward DW, Onwubiko HA, Priola SA, Caughey B (2007) Ultrasensitive detection of scrapie prion protein using seeded conversion of recombinant prion protein. Nat Methods 4:645–650PubMedCrossRefGoogle Scholar
  3. Atarashi R, Wilham JM, Christensen L, Hughson AG, Moore RA, Johnson LM, Onwubiko HA, Priola SA, Caughey B (2008) Simplified ultrasensitive prion detection by recombinant PrP conversion with shaking. Nat Methods 5:211–212PubMedCrossRefGoogle Scholar
  4. Atarashi R, Satoh K, Sano K, Fuse T, Yamaguchi N, Ishibashi D, Matsubara T, Nakagaki T, Yamanaka H, Shirabe S, Yamada M, Mizusawa H, Kitamoto T, Klug G, McGlade A, Collins SJ, Nishida N (2011) Utrasensitive human prion detection in cerebrospinal fluid by real-time quaking-induced conversion. Nat Med 17:175–178PubMedCrossRefGoogle Scholar
  5. Barclay GR, Houston EF, Halliday SI, Farquhar CF, Turner ML (2002) Comparative analysis of normal prion protein expression on human, rodent, and ruminant blood cells by a panel of prion antibodies. Transfusion 42:517–526PubMedCrossRefGoogle Scholar
  6. Bennett PG, Ball J (2009) vCJD Risk Assessment Calculations for a Patient With Multiple Routes of Exposure. http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/documents/digitalasset/dh_100337.pdf. Accessed 15 September 2011
  7. Bessos H, Drummond O, Prowse C, Turner M, MacGregor I (2001) The release of prion protein from platelets during storage of apheresis platelets. Transfusion 41:61–66PubMedCrossRefGoogle Scholar
  8. Bieschke J, Weber P, Sarafoff N, Beekes M, Giese A, Kretzschmar H (2004) Autocatalytic self-propagation of misfolded prion protein. Proc Natl Acad Sci USA 101:12207–12211CrossRefGoogle Scholar
  9. Bishop MT, Ritchie DL, Will RG, Ironside JW, Head MW, Thomson V, Bruce M, Manson JC (2008) No major change in vCJD agent strain after secondary transmission via blood transfusion. Plos One 3:e2878PubMedCrossRefGoogle Scholar
  10. Bons N, Lehmann S, Mestre-France N, Dormont D, Brown P (2002) Brain and buffy coat transmission of bovine spongiform encephalopathy to the primate Microcebus murinus. Transfusion 42:513–516PubMedCrossRefGoogle Scholar
  11. Brown P, Gibbs CJ, Rodgers-Johnson P, Asher DM, Sulima PM, Bacote A, Goldfarb LG, Gajdusek DC (1994) Human spongiform encephalopathy: The National Institute of Health series of 300 cases of experimentally transmitted disease. Ann Neurol 35:513–529PubMedCrossRefGoogle Scholar
  12. Brown P, Rohwer RG, Dunstan BC, MacAuley C, Gajdusek DC, Drohan WN (1998) The distribution of infectivity in blood components and plasma derivatives in experimental models of transmissible spongiform encephalopathy. Transfusion 38:810–816PubMedCrossRefGoogle Scholar
  13. Brown P, Cervenakova L, McShane LM, Barber P, Rubenstein R, Drohan WN (1999) Further studies of blood infectivity in an experimental model of transmissible spongiform encephalopathy, with an explanation of why blood components do not transmit Creutzfeldt-Jakob disease in humans. Transfusion 39:1169–1179PubMedCrossRefGoogle Scholar
  14. Brown P (2000) BSE and transmission through blood. Lancet 356:955–956PubMedCrossRefGoogle Scholar
  15. Burdick MD, Pifat DY, Petteway SR, Cai K (2006) Clearance of prions during plasma protein manufacture. Transfus Med Rev 20:57–62PubMedCrossRefGoogle Scholar
  16. Burthem J, Urban B, Pain A, Roberts DJ (2001) The normal cellular prion protein is strongly expressed in myeloid dendritic cells. Immunobiology 98:3733–3738Google Scholar
  17. Casaccia P, Ladogana A, Xi YG, Pocchiari M (1989) Levels of infectivity in the blood throughout the incubation period of hamsters peripherally injected with scrapie. Arch Virol 108:146–149CrossRefGoogle Scholar
  18. Castilla J, Saa P, Soto C (2005) Detection of prions in blood. Nat Med 11:982–985PubMedGoogle Scholar
  19. Caughey B, Horiuchi M, Demaimay Raymond GJ (1999) Assays of protease-resistant prion protein and its formation. Methods Enzymol 309:122–133PubMedCrossRefGoogle Scholar
  20. Cervenakova L, Yakovleva O, McKenzie C, Kolchinsky S, McShane L, Drohlan WN, Brown P (2003) Similar levels of infectivity in the blood of mice infected with human-derived vCJD and GSS strains of transmissible spongiform encephalopathy. Transfusion 43:1687–1694PubMedCrossRefGoogle Scholar
  21. Chohan G, LLewelyn C, Mackenzie J, Cousens S, Kennedy A, Will R, Hewitt P (2010) Variant Creutzfeldt-Jakob disease in a transfusion recipient: coincidence or cause? Transfusion 50:1003–1006PubMedCrossRefGoogle Scholar
  22. Choi EM, Geschwind MD, Deering C, Pomeroy K, Kuo A, Miller BL, Safar JG, Prusiner SB (2009) Prion proteins in subpopulations of white blood cells from patients with sporadic Creutzfeldt-Jakob disease. Lab Invest 89:624–635PubMedCrossRefGoogle Scholar
  23. Clarke P, Ghani AC (2005) Projections of the future course of the primary vCJD epidemic in the UK: inclusion of subclinical infection and the possibility of wider genetic susceptibility. J R Soc Interface 2:19–31PubMedCrossRefGoogle Scholar
  24. Clewley JP, Kelly CM, Andrews N, Vogliqi K, Mallinson G, Kaisar M, Hilton DA, Ironside JW, Edwards P, McCardle M, Ritchie DL, Dabagian R, Ambrose HE, Gill ON (2009) Prevalence of disease related prion protein in anonymous tonsil specimens in Britain: a cross sectional opportunistic survey. Br Med J 338:b1442CrossRefGoogle Scholar
  25. Comoy E, Jaffre N, Mikol J, Durand V, Jas-Duval C, Lebon V, Cheval J, Quadrio I, Lescoutra-Etchegaray N, Streichenberger, Haik S, Sumian C, Perret-Liaudet A, Eloit M, Hantraye P, Brown P, Deslys JP (2012) A new neurological disease in primates inoculated with prion-infected blood or blood components. Prion 6S:19–20CrossRefGoogle Scholar
  26. De Marco MF, Linehan J, Gill ON, Clewley JP, Brandner S (2010) Large-scale immunohistochemical examination for lymphoreticular prion protein in tonsil specimens collected in Britain. J Pathol 222:380–387PubMedCrossRefGoogle Scholar
  27. Deleault NR, Harris BT, Rees JR, Supattapone S (2007) Formation of native prions from minimal components in vitro. Proc Natl Acad Sci USA 104:9741–9746PubMedCrossRefGoogle Scholar
  28. Deslys JP, Lasmezas C, Dormont D (1994) Selection of specific strains in iatrogenic Creutzfeldt-Jakob disease. Lancet 343:848–849PubMedCrossRefGoogle Scholar
  29. Diringer H (1984) Sustained viremia in experimental hamster scrapie. Arch Virol 82:105–109PubMedCrossRefGoogle Scholar
  30. Durig J, Giese A, Schulz-Schaeffer W, Rosenthal C, Schmucker U, Bieschke J, Duhrsen U, Kretzschmar HA (2000) Differential constitutive and activation-dependent expression of prion protein in human peripheral blood leucocytes. Br J Haematol 108:488–495PubMedCrossRefGoogle Scholar
  31. Edgeworth JA, Farmer M, Sicilia A, Tavares P, Beck J, Campbell T, Lowe J, Mead S, Rudge P, Collinge J, Jackson GS (2011) Detection of prion infection in variant Creutzfeldt-Jakob disease: a blood-based assay. Lancet 377:487–493PubMedCrossRefGoogle Scholar
  32. Foster PR, Welch AG, McLean C, Griffin BD, Hardy JC, Bartley A, MacDonald S, Bailey AC (2000) Studies on the removal of abnormal prion protein by processes used in the manufacture of human plasma products. Vox Sang 78:86–95PubMedCrossRefGoogle Scholar
  33. Garske T, Ghaini AC (2010) Uncertainty in the tail of the variant Creutzfeldt-Jakob disease epidemic in the UK. PLoS One 5:e15626PubMedCrossRefGoogle Scholar
  34. Gregori L, McCombie N, Palmer D, Birch P, Sowemimo-Coker SO, Giulivi A, Rohwer RG (2004a) Effectiveness of leucoreduction for removal of infectivity of transmissible spongiform encephalopathies from blood. Lancet 364:529–531PubMedCrossRefGoogle Scholar
  35. Gregori L, Maring JA, MacAuley C, Dunston B, Rentsch M, Kempf C, Rohwer RG (2004b) Partitioning of TSE infectivity during ethanol fractionation of human plasma. Biologicals 32:1–10PubMedCrossRefGoogle Scholar
  36. Gregori L, Lambert BC, Gurgel PV, Gheorghiu L, Edwardson P, Lathrop JT, MacAuley C, Carbonell RG, Burton SJ, Hammond D, Rohwer RG (2006a) Reduction of transmissible spongiform encephalopathy infectivity from red blood cells with prion protein affinity ligands. Transfusion 46:1152–1161PubMedCrossRefGoogle Scholar
  37. Gregori L, Gurgel PV, Lathrop JT, Edwardson P, Lambert BC, Carbonell RG, Burton SJ, Hammond DJ, Rohwer RG (2006b) Reduction of infectivity of endogenous transmissible spongiform encephalopathies present in blood by adsorption to selective affinity resins. Lancet 368:2226–2230PubMedCrossRefGoogle Scholar
  38. Gregori L, Yang H, Anderson S (2011) Estimation of variant Creutzfeldt-Jakob disease infectivity titres in human blood. Transfusion 51:2596–2603PubMedCrossRefGoogle Scholar
  39. Haddon DJ, Hughes MR, Antignano F, Westaway D, Cashman NR, McNagny KM (2009) Prion protein expression and release by mast cells after activation. J Infect Dis 200:827–831PubMedCrossRefGoogle Scholar
  40. Hartwell RC, Nelson MS, Kislan MM, Stenland CJ, Miller JLC, Pifat DY, Petteway SR, Cai K (2005) An improved Western blot assay to assess the clearance of prion protein from plasma-derived therapeutic proteins. J Virol Methods 125:187–193PubMedCrossRefGoogle Scholar
  41. Head MW, Yull HM, Ritchie DL, Bishop MT, Ironside JW (2009) Pathological investigation of the first blood donor and recipient pair linked by transfusion-associated variant Creutzfeldt-Jakob disease transmission. Neuropathol Appl Neurobiol 35:433–436PubMedCrossRefGoogle Scholar
  42. Health Protection Agency (2007) Fourth case of transfusion-associated variant-CJD infection. Health Protect Report 2007; 1: 2–3. http://www.hpa.org.uk/hpr/archives/2007/hpr0307.pdf. Accessed September 15, 2011
  43. Health Protection Agency (2012) Summary results of the second national survey of abnormal prion protein prevalence in archived appendix specimens. Health Protection Report 6: 3–4. http://www.hpa.org/hpr/archives/2012/news3212.htm#bnrmlprn. Accessed September 11, 2012
  44. Herzog C, Sales N, Etchegaray N, Charbonnier A, Freire S, Dormant D, Deslys JP, Lasmezas CI (2004) Tissue distribution of bovine spondiform encephalopathy agent in primates after intravenous or oral infection. Lancet 363:422–428PubMedCrossRefGoogle Scholar
  45. Herzog C, Riviere J, Lescoutra-Eschegaray N, Charbonnier A, Leblanc V, Sales N, Deslys JP, Lasmezas CI (2005) PrPTSE distribution in a primate model of variant, sporadic and iatrogenic Creutzfeldt-Jakob disease. J Virol 70:14339–14345CrossRefGoogle Scholar
  46. Hewitt PE, Llewelyn CA, Mackenzie J, Will RG (2006) Creutzfeldt-Jakob disease and blood transfusion: results of the UK Transfusion Medicine Epidemiological Review study. Vox Sang 91:221–230PubMedCrossRefGoogle Scholar
  47. Hilton DA, Ghani AC, Conyers L, Edwards P, McCardle L, Ritchie D, Penney M, Hegazy D, Ironside JW (2004) Prevalence of lymphoreticular prion protein accumulation in UK tissue samples. J Pathol 203:733–739PubMedCrossRefGoogle Scholar
  48. Holada K, Simak J, Risitano AM, Maciejewski J, Young NS, Vostal JG (2002a) Activated platelets of patients with paroxysmal nocturnal hemoglobinuria express cellular prion protein. Blood 100:341–343PubMedCrossRefGoogle Scholar
  49. Holada K, Vostal JG, Theisen PW, MacAuley C, Gregori L, Rohwer RG (2002b) Scrapie infectivity in hamster blood is not associated with platelets. J Virol 76:4649–4650PubMedCrossRefGoogle Scholar
  50. Houston F, Foster JD, Chong A, Hunter N, Bostock CJ (2000) Transmission of BSE by blood transfusion in sheep. Lancet 356:999–1000PubMedCrossRefGoogle Scholar
  51. Houston F, McCutcheon S, Goldman W, Chong A, Foster J, Siso S, Gonzalez L, Jeffrey M, Hunter N (2008) Prion diseases are efficiently transmitted by transfusion in sheep. Blood 112:4739–4745PubMedCrossRefGoogle Scholar
  52. Hunter N, Foster J, Chong A, McCutcheon S, Parnham D, Eaton S, MacKenzie C, Houston F (2002) Transmission of prion diseases by blood transfusion. J Gen Virol 83:2897–2905PubMedGoogle Scholar
  53. Jones M, Peden AH, Prowse CV, Groener A, Manson JC, Turner ML, Ironside JW, MacGregor IR, Head MW (2007) In vitro amplification and detection of variant Creutzfeldt-Jakob disease PrPSc. J Pathol 213:21–26PubMedCrossRefGoogle Scholar
  54. Jones M, Peden AH, Yull H, Wight D, Bishop MT, Prowse CV, Turner ML, Ironside JW, MacGregor IR, Head MW (2009) Human platelets as a substrate source for the in vitro amplification of the abnormal prion protein (PrP) associated with variant Creutzfeldt-Jakob disease. Transfusion 49:376–384PubMedCrossRefGoogle Scholar
  55. Kocisko DA, Come JH, Priola S, Chesebro B, Raymond GJ, Lansbury PT, Caughey B (1994) Cell-free formation of protease-resistant prion protein. Nature 370:471–474PubMedCrossRefGoogle Scholar
  56. Kuroda Y, Gibbs CJ, Amyx HL, Gajdusek DC (1983) Creutzfeldt-Jakob disease in mice: persistent viremia and preferential replication of virus in low-density lymphocytes. Infect Immun 41:154–161PubMedGoogle Scholar
  57. Lacroux C, Bougard D, Litaise C, Simmons H, Corbiere F, Dernis D, Tardivel R, Morel N, Simon S, Lugan S, Costes P, Weisbecker JL, Schlcher F, Grassi J, Coste J Andeoletti O (2012) Impact of leucocyte depletion and prion reduction filters on TSE blood borne transmission. PLoS One 7:e42019PubMedGoogle Scholar
  58. Lasmezas CI, Fournier JG, Nouvel V, Boe H, Marce D, Lamoury F, Kopp N, Hauw JJ, Ironside JW, Bruce M, Dormont D, Deslys JP (2001) Adaptation of the bovine spongiform encephalopathy agent to primates and comparison with Creutzfeldt-Jakob disease: Implications for human health. Proc Natl Acad Sci USA 98:4142–4147.Google Scholar
  59. Lasmezas CI, Comoy E, Hawkins S, Herzog C, Mouthon F, Timm K, Auvre F, Corriea E, Lescoutra-Etchagaray N, Sales N, Wells G, Brown P, Deslys JP (2005) Risk of oral infection with bovine spongiform encephalopathy agent in primates. Lancet 365:781–783PubMedGoogle Scholar
  60. Lee DC, Stenland CJ, Hartwell RC, Ford EK, Cai K, Miller JLC, Gilligan KJ, Rubenstein R, Fournel M, Petteway SR (2000) Monitoring plasma processing steps with a sensitive Western blot assay for the detection of the prion protein. J Virol Methods 84:77–89PubMedCrossRefGoogle Scholar
  61. Lee DC, Stenland CJ, Miller JL, Cai K, Ford EK, Gilligan KJ, Hartwell RC, Terry JC, Rubenstein R, Fournel M, Petteway SR (2001) Direct relationship between the partitioning of pathogenic prion protein and transmissible spongiform encephalopathy infectivity during the purification of plasma proteins. Transfusion 41:449–455PubMedCrossRefGoogle Scholar
  62. Lescoutra-Etchegaray N, Jaffre N, Culeux A, Sumian C, Durand V, Deslys JP, Comoy E (2012) Prion removal PCapt device delays onset of atypical neurological disease observed in primates exposed to BSE-infected blood products. Prion 6S:141PubMedCrossRefGoogle Scholar
  63. Li R, Liu D, Zanusso G, Liu T, Fayen JD, Huang JH, Petersen RB, Gambetti P, Sy MS (2001) The expression and potential function of cellular prion protein in human lymphocytes. Cell Immunol 207:49–58PubMedCrossRefGoogle Scholar
  64. Llewelyn CA, Hewitt PE, Knight RS, Amar K, Cousens S, Mackenzie J, Will RG (2004) Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet 363:417–421PubMedCrossRefGoogle Scholar
  65. MacGregor I, Hope J, Barnard G, Kirby L, Drummond O, Pepper D, Hornsey V, Barclay R, Bessos H, Turner M, Prowse C (1999) Application of time-resolved fluoroimmunoassay for the analysis of normal human prion protein in human blood and its components. Vox Sang 77:88–96PubMedCrossRefGoogle Scholar
  66. Manuelidis EE, Gorgacz EJ, Manuelidis L (1978) Viremia in experimental Creutzfeldt-Jakob disease. Science 200:1069–1071PubMedCrossRefGoogle Scholar
  67. Manuelidis EE, Kim JH, Mericangas JR, Manuelidis L (1985) Transmission to animals of Creutzfeldt-Jakob disease from human blood. Lancet 2:896–897PubMedCrossRefGoogle Scholar
  68. McCutcheon S, Blanco ARA, Houston EF, de Wolf C, Tan BC, Smith A, Groschup MH, Hunter N, Hornsey VS, MacGregor IR, Prowse CV, Turner M, Manson JC (2011) All clinically-relevant blood components transmit prion disease following a single blood transfusion: A sheep model of vCJD. PLoS One 6:e23169PubMedCrossRefGoogle Scholar
  69. McGuire LI, Peden AH, Orru CD, Wilham JM, Appleford NE, Mallinson G, Andrews M, Head MW, Caughey B, Will RG, Knight RSG, Green AJE (2012) Real time quaking-induced conversion analysis of cerebrospinal fluid in sporadic Creutzfeldt-Jakob disease. Ann Neurol 72:278–285PubMedCrossRefGoogle Scholar
  70. Orru CD, Wilham JM, Raymond LD, Kuhn F, Schroeder B, Raeber AJ, Caughey B (2011) Prion disease blood test using immunoprecipitation and improved quaking-induced conversion. M Biol 2:e00078–11Google Scholar
  71. Peden AH, Head MW, Ritchie DL, Bell JE, Ironside JW (2004) Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet 364:527–529PubMedCrossRefGoogle Scholar
  72. Peden AH, Head MW, Jones M, MacGregor I, Turner M, Ironside J (2008) Advances in the development of a screening test for variant Creutzfeldt-Jakob disease. Expert Opin Med Diag 2:207–219CrossRefGoogle Scholar
  73. Peden A, McCardle L, Head MW, Love S, Ward HJT, Cousens SN, Keeling DM, Millar CM, Hill FGH, Ironside JW (2010) Variant CJD infection in the spleen of a neurologically asymptomatic UK adult patient with haemophilia. Haemophilia 16:296–304PubMedCrossRefGoogle Scholar
  74. Peden AH, McGuire LI, Appleford NEJ, Mallinson G, Wilham JM, Orru CD, Caughey B, Ironside J, Knight RS, Will RG, Green AJE, Head MW (2012) Sensitive and specific detection of ­sporadic Creutzfeldt-Jakob disease brain prion protein using real-time quaking-induced ­conversion. J Gen Virol 93:438–449PubMedCrossRefGoogle Scholar
  75. Perini F, Vidal R, Ghetti B, Tagliavini F, Frangione B, Prelli F (1996) PRP27-30 is a normal soluble protein fragment released by human platelets. Biochem Biophys Res Commun 223:572–577PubMedCrossRefGoogle Scholar
  76. Puopolo M, Ladogana A, Vetrugno V, Pocchiari M (2011) Transfusion of sporadic Creutzfeldt-Jakob disease by blood transfusion: risk factor or possible biases. Transfusion 51:1556–1566PubMedCrossRefGoogle Scholar
  77. Saa P, Castilla J, Soto C (2006) Presymptomatic detection of prions in blood. Science 313:92–94PubMedCrossRefGoogle Scholar
  78. Saborio GP, Permanne B, Soto C (2001) Sensitive detection of pathological prion protein by cyclic amplification of protein misfolding. Nature 411:810–813PubMedCrossRefGoogle Scholar
  79. Safar J, Geschwind MD, Deering C, Didorenko S, Sattavat M, Sanchez H, Serban A, Vey M, Baron H, Giles K, Miller BL, DeArmond SJ, Prusiner SB (2005) Diagnosis of human prion protein. Proc Natl Acad Sci USA 102:3501–3506PubMedCrossRefGoogle Scholar
  80. Siso S, Gonzalez L, Houston F, Hunter N, Martin S, Jeffrey M (2006) The neuropathological phenotype of experimental ovine BSE is maintained after blood transfusion. Blood 108:745–748PubMedCrossRefGoogle Scholar
  81. Siso S, Jeffrey M, Houston F, Hunter N, Martin S, Gonzalez L (2009) Pathological phenotype of sheep scrapie after blood transfusion. J Comp Pathol 142:27–35PubMedCrossRefGoogle Scholar
  82. Sowemimo-Coker S, Kascsak R, Kim A, Andrade F, Pesci S, Kascsak R, Meeker C, Carp R, Brown P (2005) removal of exogenous (spiked) and endogenous prion infectivity from red cells with a new prototype of leucoreduction filter. Transfusion 45:1839–1844PubMedCrossRefGoogle Scholar
  83. Sowemimo-Coker SO, Demczyk CA, Andrade F, Baker CA (2010) Evaluation of prion infectivity from red blood cells with prion reduction filters using a new rapid and highly sensitive cell culture-based infectivity assay. Transfusion 50:980–988PubMedCrossRefGoogle Scholar
  84. Spongiform Encephalopathy Advisory Committee (2008) Position Statement: Prevalence of Subclinical Variant Creutzfeldt-Jakob Disease Infections. http://webarchive.nationalarchives.gov.uk/20110316162913/http://www.seac.gov.uk/statements/state-cjd-infections.pdf. Accessed September 15, 2011
  85. Tattum MH, Jones S, Pal S, Collinge J, Jackson GS (2010) Discrimination between prion-infected and normal blood samples by protein misfolding cyclic amplification. Transfusion 50:996–1002PubMedCrossRefGoogle Scholar
  86. Thorne L, Terry LA (2008) In vitro amplification of PrPSc derived from the brain and blood of sheep infected with scrapie. J Gen Virol 89:3177–3184PubMedCrossRefGoogle Scholar
  87. Turner M (2006) Transfusion safety with regards to prions: ethical, legal and societal considerations. Transfus Clin Biol 13:317–319PubMedCrossRefGoogle Scholar
  88. Williams L, Brown P, Ironside J, Gibson S, Will R, Ritchie D, Kreil TR, Abee C (2007) Clinical, neuropathological and immunocytochemical features of sporadic and variant forms of Creutzfeldt-Jakob disease in the squirrel monkey (Saimiri sciureus). J Gen Virol 88:688–695PubMedCrossRefGoogle Scholar
  89. Wroe SJ, Pal S, Siddique D, Hyare H, Macfarlane R, Joiner S, Linehan JM, Brandner S, Wadsworth JD, Hewitt P, Collinge J (2006) Clinical presentation and pre-mortem diagnosis of variant Creutzfeldt-Jakob disease associated with blood transfusion: a case report. Lancet 368:2061–2067PubMedCrossRefGoogle Scholar
  90. Yuan J, Xiao X, McGeehan J, Dong Z, Cali I, Fujioka H, Kong Q, Kneale G, Gambetti P, Zou WQ (2006) Insoluble aggregates and protease-resistant conformers of prion protein in uninfected human brains. J Biol Chem 281:34848–34858PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Alexander H. Peden
    • 1
  • Mark W. Head
    • 1
  • James W. Ironside
    • 1
  1. 1.National Creutzfeldt-Jakob Disease Research & Surveillance Unit, School of Clinical SciencesUniversity of Edinburgh, Western General HospitalEdinburghUK

Personalised recommendations